Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AWHOTCMKTS:GNWSFNASDAQ:MYMDNYSE:NAVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAWHAspira Women's Health$0.08-12.5%$0.08$0.08▼$1.73$2.44M2.011.50 million shs4.31 million shsGNWSFStageZero Life Sciences$0.02-9.1%$0.01$0.00▼$1.27$1.51M0.2826,719 shs20,100 shsMYMDMyMD Pharmaceuticals$0.13-8.8%$0.17$1.75▼$63.90$297K2.15134,123 shs4.01 million shsNAVBNavidea Biopharmaceuticals$0.00-50.0%$0.00$0.00▼$0.13$10K1.78,576 shs15,514 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAWHAspira Women's Health0.00%0.00%0.00%-22.05%-93.83%GNWSFStageZero Life Sciences0.00%-0.21%+698.33%+698.33%+1,496.67%MYMDMyMD Pharmaceuticals-8.79%-10.23%-28.04%-65.14%-93.36%NAVBNavidea Biopharmaceuticals-50.00%-50.00%-87.50%-75.00%-50.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAWHAspira Women's Health0.8476 of 5 stars3.50.00.00.00.00.00.0GNWSFStageZero Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAWHAspira Women's Health 3.00Buy$5.506,607.32% UpsideGNWSFStageZero Life Sciences 0.00N/AN/AN/AMYMDMyMD Pharmaceuticals 0.00N/AN/AN/ANAVBNavidea Biopharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAWHAspira Women's Health$9.18M0.27N/AN/A($0.23) per share-0.36GNWSFStageZero Life Sciences$4.15M0.36N/AN/A($0.02) per share-1.20MYMDMyMD PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/ANAVBNavidea Biopharmaceuticals$8.13K1.23N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAWHAspira Women's Health-$16.69M-$0.98N/A∞N/A-165.07%N/A-267.23%8/11/2025 (Estimated)GNWSFStageZero Life Sciences-$6.86M-$0.28N/A∞N/A-200.26%N/A-165.13%N/AMYMDMyMD Pharmaceuticals-$4MN/A0.00∞N/AN/A-179.05%-108.14%N/ANAVBNavidea Biopharmaceuticals-$15.18MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAWHAspira Women's Health$1.041,268.29%N/AN/A N/AGNWSFStageZero Life SciencesN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAWHAspira Women's HealthN/A0.750.70GNWSFStageZero Life SciencesN/A1.151.08MYMDMyMD PharmaceuticalsN/A0.620.62NAVBNavidea BiopharmaceuticalsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAWHAspira Women's Health12.19%GNWSFStageZero Life Sciences0.02%MYMDMyMD Pharmaceuticals9.64%NAVBNavidea Biopharmaceuticals0.01%Insider OwnershipCompanyInsider OwnershipAWHAspira Women's Health4.30%GNWSFStageZero Life SciencesN/AMYMDMyMD Pharmaceuticals2.12%NAVBNavidea Biopharmaceuticals43.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAWHAspira Women's Health11029.76 million16.92 millionNo DataGNWSFStageZero Life Sciences8063.00 millionN/ANot OptionableMYMDMyMD Pharmaceuticals62.37 million2.32 millionOptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableGNWSF, AWH, MYMD, and NAVB HeadlinesRecent News About These CompaniesNavidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock SplitMay 21, 2025 | businesswire.comNavidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax AssetsMarch 31, 2025 | businesswire.comNavidea Biopharmaceuticals Inc. (NAVB) Latest Pre Market TradesDecember 23, 2024 | nasdaq.comNavidea Biopharmaceutical (OTC:NAVB) Stock Quotes, Forecast and News SummaryOctober 28, 2024 | benzinga.comNavidea Biopharmaceuticals gets grant for treatment of flaviviridae family virus infectionsAugust 22, 2024 | pharmaceutical-technology.comPNavidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024July 3, 2024 | businesswire.comNavidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024June 20, 2024 | businesswire.comSK Biopharmaceuticals Co. Ltd.May 25, 2024 | wsj.comDay One Biopharmaceuticals, Inc. Common Stock (DAWN)May 3, 2024 | nasdaq.comNavidea Biopharmaceuticals files patent for polymeric compound for treating diseases involving macrophagesMarch 6, 2024 | pharmaceutical-technology.comPNavidea Biopharmaceuticals gets grant for method for conjugating metal chelating agent to functionalized dextranMarch 5, 2024 | pharmaceutical-technology.comPNavidea Biopharmaceutical Stock (OTC:NAVB), Short Interest ReportFebruary 23, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB) Dividends: History, Yield and DatesFebruary 22, 2024 | benzinga.comNavidea Biopharmaceutical Stock (OTC:NAVB) Insider TradesFebruary 22, 2024 | benzinga.comCentral Ohio public company voluntarily deregisters stockJanuary 29, 2024 | bizjournals.comNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting ObligationsJanuary 26, 2024 | finance.yahoo.comNavidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting ObligationsJanuary 26, 2024 | finance.yahoo.comSuzhou Zelgen Biopharmaceuticals Co Ltd (688266)January 11, 2024 | investing.comNavidea settles litigation with Capital Royalty, stock rallies 30%December 1, 2023 | msn.comNavidea Biopharmaceuticals, CRG Settle All Ongoing LitigationDecember 1, 2023 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGNWSF, AWH, MYMD, and NAVB Company DescriptionsAspira Women's Health NASDAQ:AWH$0.08 -0.01 (-12.49%) As of 04/16/2025Aspira Women's Health, Inc. engages in the provision of bio-analytic and diagnostic services. Its product, OVA1, is a serum test for identifying women of having malignant ovarian tumor. Its bio-analytical solutions helps physicians diagnose, treat, and improve gynecologic health outcomes for women. The company was founded on December 9, 1993 and is headquartered in Austin, TX.StageZero Life Sciences OTCMKTS:GNWSF$0.02 0.00 (-9.11%) As of 06/25/2025StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.MyMD Pharmaceuticals NASDAQ:MYMD$0.13 -0.01 (-8.79%) As of 06/26/2025MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Navidea Biopharmaceuticals NYSE:NAVB$0.0001 0.00 (-50.00%) As of 06/27/2025 03:04 PM EasternNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
